Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Lakefront Biotherapeutics is a biopharmaceutical company headquartered in Mechelen, Belgium, dedicated to developing innovative therapeutics for serious diseases. The company specializes in immunology-focused drug development, with a strategic emphasis on T-cell engager programs designed to address severe inflammatory and autoimmune conditions. Lakefront Biotherapeutics leverages precision medicine approaches to target specific disease mechanisms, particularly through BCMA-targeted T cell engagers that aim to eliminate pathogenic B cells implicated in immune-mediated diseases. The company operates through collaborations with leading pharmaceutical partners to advance its clinical and preclinical pipeline. Founded in 1999, Lakefront Biotherapeutics represents a repositioned research-driven organization focused on delivering transformative treatment options for patients with unmet medical needs in the immunology space.
Margins and capital returns are both well above average: 45.08% operating margin, ROIC at 15.46%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Negative free cash flow of -€271M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€1.04B
Net Income (TTM)
€489M
Op. Margin
57.14%
ROIC
15.46%
Cash Flow & Balance Sheet
FCF (TTM)
-€310M
Op. Cash Flow (TTM)
-€57M
Net Debt
-€2.99B
Net Cash Position
Cash & Equiv.
€3.00B
Continue Research